Alizé Pharma III Raises €1.8M in First Financing

Alizé Pharma III SAS, a Lyon, France-based Alizé Pharma company specialized in the development of biopharma products to treat metabolic disorders and rare diseases, raised €1.8m (approx. USD $1.94m) in a first financing round.

Backers included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting.

The company intends to use the funds to conduct a pharmacology and lead optimization program on a family of peptides with anabolic effects on the bone. The I-HBD1 program will be performed in collaboration with Alizé Pharma III’s US partner New Paradigm Therapeutics Inc., a spin-off from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons. The aim of the program is to select a drug candidate that will enter development for the treatment of osteoporosis and other diseases with impaired bone metabolism in 2016.

Founded in 2014 and led by Thierry Abribat, president, Alizé Pharma III has acquired exclusive worldwide rights to develop and commercialize a family of new peptides with bone anabolic properties. Its I-HBD1 program aims to optimize and develop a new peptide derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2).

Created in 2007, Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The group has raised €15.1m from private and institutional investors to advance two programs to the clinical phase and has also signed its first industrial partnership.
It includes: Alizé Pharma SAS, which is working on a peptide derived from unacylated ghrelin (AZP-531). This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes; and Alizé Pharma II SAS, which is focusing on the development of ASPAREC®, a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL).



Join the discussion